24 May 2013
Keywords: USA, FDA, AstraZeneca, Brilinta, Savient, Krystexxa, Sale of company
Article | 15 September 2010
The US Food and Drug Administration has extended the time to complete its review of the New Drug Application for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 September 2010
23 May 2013
© 2013 thepharmaletter.com